VanEck Biotech ETF (NASDAQ:BBH) Short Interest Down 17.6% in January

VanEck Biotech ETF (NASDAQ:BBH) was the recipient of a significant decrease in short interest during the month of January. As of January 15th, there was short interest totalling 1,400 shares, a decrease of 17.6% from the December 31st total of 1,700 shares. Based on an average daily trading volume, of 10,800 shares, the short-interest ratio is currently 0.1 days.

VanEck Biotech ETF Trading Up 0.3 %

NASDAQ:BBH traded up $0.54 during trading hours on Monday, reaching $165.79. The company had a trading volume of 3,517 shares, compared to its average volume of 11,331. VanEck Biotech ETF has a 1-year low of $151.35 and a 1-year high of $183.64. The business’s 50 day moving average price is $161.97 and its 200-day moving average price is $170.83.

VanEck Biotech ETF Announces Dividend

The firm also recently announced a dividend, which was paid on Tuesday, December 24th. Stockholders of record on Monday, December 23rd were given a dividend of $1.2517 per share. The ex-dividend date of this dividend was Monday, December 23rd.

Hedge Funds Weigh In On VanEck Biotech ETF

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Truvestments Capital LLC purchased a new stake in VanEck Biotech ETF in the 3rd quarter valued at about $44,000. FSA Wealth Management LLC purchased a new stake in shares of VanEck Biotech ETF in the 3rd quarter valued at $54,000. Coastline Trust Co acquired a new position in VanEck Biotech ETF during the 3rd quarter worth about $59,000. Wilmington Savings Fund Society FSB purchased a new position in VanEck Biotech ETF during the 3rd quarter valued at about $166,000. Finally, Tyler Stone Wealth Management grew its position in VanEck Biotech ETF by 79.5% in the 3rd quarter. Tyler Stone Wealth Management now owns 1,472 shares of the company’s stock valued at $261,000 after acquiring an additional 652 shares in the last quarter. 32.05% of the stock is owned by hedge funds and other institutional investors.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.